NASDAQ, CYTK - Cytokinetics
We are a biopharmaceutical company, incorporated in Delaware in 1997, focused on
developing small molecule therapeutics for the treatment of cardiovascular
diseases and cancer. Our current development activities are primarily directed
to advancing multiple drug candidates through clinical trials with the objective
of determining the intended pharmacodynamic effect or effects in two principal
diseases: heart failure and cancer. Our drug development pipeline consists of a
drug candidate, CK-1827452, being developed in both an intravenous and oral
formulation for the potential treatment of heart failure, and three drug
candidates, ispinesib, SB-743921 and GSK-923295, each being developed in an
intravenous formulation for the potential treatment of cancer. Our drug
candidates are all novel small molecules that arose from our research activities
and are directed toward the biology of the cytoskeleton. ...
Read SEC Filing on NASDAQ.com »